Brookline Capital Markets Starts Progenics Pharmaceuticals (PGNX) at Buy

July 29, 2019 4:22 PM EDT
Get Alerts PGNX Hot Sheet
Price: $4.10 --0%

Rating Summary:
    8 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Progenics Pharmaceuticals (NASDAQ: PGNX) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Progenics Pharmaceuticals click here. For more ratings news on Progenics Pharmaceuticals click here.

Shares of Progenics Pharmaceuticals closed at $5.18 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage